Investigational Drug Details
| Drug ID: | D033 |
| Drug Name: | Alanine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00160 |
| DrugBank Description: | Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. |
| PubChem ID: | 5950 |
| CasNo: | 56-41-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C[C@H](N)C(O)=O |
| Structure: |
|
| InChiKey: | QNAYBMKLOCPYGJ-REOHCLBHSA-N |
| Molecular Weight: | 89.0932 |
| DrugBank Targets: | Serine--pyruvate aminotransferase; Alanine aminotransferase 1; Cysteine desulfurase, mitochondrial; Proton-coupled amino acid transporter 1; Large neutral amino acids transporter small subunit 2; Alanine--glyoxylate aminotransferase 2, mitochondrial; Alanine--tRNA ligase, cytoplasmic; Neutral amino acid transporter A; 4-aminobutyrate aminotransferase, mitochondrial; Kynureninase; Alanine--tRNA ligase, mitochondrial; 5-phosphohydroxy-L-lysine phospho-lyase; Alanine aminotransferase 2 |
| DrugBank MoA: | L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance. |
| DrugBank Pharmacology: | Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids. |
| DrugBank Indication: | Used for protein synthesis. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0075 | NCT02681991 | PHASE4 | COMPLETED | NO | 2016-01 | 2017-07-06 | Details |
| L0388 | NCT01478971 | PHASE3 | COMPLETED | YES | 2011-10 | 2016-09-20 | Details |
| L0448 | NCT02586402 | PHASE2 | UNKNOWN | NO | 2015-10 | 2015-10-26 | Details |
| L0454 | NCT00609544 | PHASE2 | WITHDRAWN | NO | 2011-04-19 | Details | |
| L0548 | NCT01624064 | PHASE1|PHASE2 | UNKNOWN | NO | 2012-08 | 2012-06-20 | Details |
| L0629 | NCT06239129 | COMPLETED | NO | 2006-01-01 | 2024-02-02 | Details | |
| L0631 | NCT01599507 | PHASE2 | COMPLETED | NO | 2011-12 | 2014-03-03 | Details |
| L0921 | NCT01242904 | PHASE2 | COMPLETED | NO | 2010-09-30 | 2017-08-28 | Details |
| L1027 | NCT02253654 | PHASE4 | COMPLETED | YES | 2015-04-01 | 2017-05-19 | Details |
| L1117 | NCT00032435 | PHASE3 | COMPLETED | NO | 2001-05 | 2010-10-15 | Details |
| L1160 | NCT05254002 | PHASE2 | COMPLETED | NO | 2022-06-23 | 2025-03-18 | Details |
| L1177 | NCT02479451 | PHASE2 | COMPLETED | YES | 2015-10 | 2024-01-09 | Details |
| L1315 | NCT05944016 | PHASE3 | RECRUITING | NO | 2024-03-25 | 2024-12-16 | Details |
| L1325 | NCT03311581 | PHASE1 | COMPLETED | NO | 2017-09-11 | 2021-09-05 | Details |
| L1326 | NCT01323855 | PHASE1 | COMPLETED | YES | 2011-03-28 | 2018-10-02 | Details |
| L1352 | NCT00042653 | PHASE3 | COMPLETED | NO | 2002-05 | 2013-05-08 | Details |
| L1720 | NCT00454350 | PHASE4 | COMPLETED | NO | 2007-02 | 2015-05-05 | Details |
| L1779 | NCT05109520 | COMPLETED | NO | 2021-09-08 | 2022-08-30 | Details | |
| L1837 | NCT03175120 | PHASE3 | COMPLETED | YES | 2017-05-26 | 2020-03-19 | Details |
| L1985 | NCT01561976 | COMPLETED | YES | 2012-01-30 | 2017-10-16 | Details | |
| L2058 | NCT02777073 | COMPLETED | YES | 2016-03-01 | 2024-02-29 | Details | |
| L2072 | NCT02147431 | PHASE1 | COMPLETED | NO | 2014-05-21 | 2018-08-13 | Details |
| L2083 | NCT00701831 | PHASE4 | COMPLETED | NO | 2008-05 | 2010-11-04 | Details |
| L2103 | NCT06269120 | RECRUITING | NO | 2024-09-30 | 2025-03-11 | Details | |
| L2179 | NCT00839527 | PHASE3 | COMPLETED | YES | 2009-02 | 2017-01-09 | Details |
| L2213 | NCT00330330 | PHASE2 | COMPLETED | NO | 2003-02 | 2008-02-06 | Details |
| L2302 | NCT03959865 | UNKNOWN | NO | 2018-12-19 | 2019-05-22 | Details | |
| L2459 | NCT01026194 | PHASE3 | COMPLETED | YES | 2009-12 | 2014-01-16 | Details |
| L2942 | NCT02048189 | PHASE4 | TERMINATED | NO | 2012-03-08 | 2024-02-21 | Details |
| L3340 | NCT02548741 | UNKNOWN | NO | 2015-09 | 2015-09-14 | Details | |
| L3385 | NCT01588366 | PHASE1 | COMPLETED | YES | 2012-04 | 2019-03-07 | Details |
| L3451 | NCT00957060 | PHASE4 | COMPLETED | NO | 2009-07 | 2010-11-30 | Details |
| L3494 | NCT05926414 | ACTIVE_NOT_RECRUITING | NO | 2023-09-21 | 2025-03-10 | Details | |
| L3939 | NCT00755846 | PHASE2 | COMPLETED | YES | 2005-03 | 2012-02-03 | Details |
| L3946 | NCT00618995 | PHASE1 | COMPLETED | YES | 2007-08 | 2015-09-07 | Details |
| L3977 | NCT06062069 | PHASE2 | ACTIVE_NOT_RECRUITING | NO | 2023-10-19 | 2025-03-28 | Details |
| L4025 | NCT01456650 | PHASE4 | COMPLETED | NO | 2011-03 | 2014-01-15 | Details |
| L4128 | NCT00543816 | PHASE3 | TERMINATED | NO | 2003-08 | 2015-06-23 | Details |
| L4216 | NCT00948324 | PHASE4 | SUSPENDED | NO | 2008-06 | 2017-10-03 | Details |
| L4259 | NCT00543517 | PHASE3 | TERMINATED | NO | 2003-02 | 2015-02-10 | Details |
| L4379 | NCT05359341 | COMPLETED | NO | 2020-09-20 | 2022-05-03 | Details | |
| L4394 | NCT01159249 | PHASE3 | COMPLETED | NO | 2010-06 | 2020-12-17 | Details |
| L4404 | NCT01185236 | PHASE4 | UNKNOWN | NO | 2010-09 | 2010-08-19 | Details |
| L4405 | NCT01573949 | COMPLETED | YES | 2011-12 | 2020-09-04 | Details | |
| L4406 | NCT02851849 | PHASE2 | COMPLETED | NO | 2016-09 | 2018-01-12 | Details |
| L4410 | NCT02582736 | COMPLETED | NO | 2012-04 | 2015-10-21 | Details | |
| L4429 | NCT01495013 | PHASE3 | COMPLETED | NO | 2011-12 | 2016-11-21 | Details |
| L4508 | NCT04303819 | COMPLETED | NO | 2020-01-05 | 2020-06-11 | Details | |
| L4553 | NCT01792518 | PHASE3 | COMPLETED | YES | 2013-02 | 2017-03-06 | Details |
| L4623 | NCT01836523 | PHASE3 | COMPLETED | YES | 2013-11 | 2017-03-06 | Details |
| L4672 | NCT06080802 | PHASE2|PHASE3 | NOT_YET_RECRUITING | NO | 2023-11-01 | 2023-10-12 | Details |
| L4699 | NCT05067621 | PHASE2 | RECRUITING | NO | 2023-07-17 | 2024-07-29 | Details |
| L4747 | NCT02913703 | PHASE1 | COMPLETED | NO | 2017-01-11 | 2019-03-12 | Details |
| L4965 | NCT06706284 | PHASE4 | RECRUITING | NO | 2025-03-25 | 2025-03-18 | Details |
| L4983 | NCT00545584 | PHASE3 | COMPLETED | YES | 2007-04-01 | 2017-05-12 | Details |
| L5159 | NCT00528879 | PHASE3 | COMPLETED | YES | 2007-09 | 2015-10-20 | Details |
| L5303 | NCT06218342 | PHASE4 | NOT_YET_RECRUITING | NO | 2024-02-15 | 2024-01-23 | Details |
| L5383 | NCT02932475 | PHASE3 | TERMINATED | YES | 2017-05-25 | 2023-06-26 | Details |
| L5439 | NCT01689142 | PHASE3 | COMPLETED | NO | 2012-09 | 2014-06-05 | Details |
| L5513 | NCT06203275 | PHASE3 | NOT_YET_RECRUITING | NO | 2024-01 | 2024-01-12 | Details |
| L5547 | NCT02985242 | PHASE4 | TERMINATED | NO | 2017-06-12 | 2018-09-27 | Details |
| L5555 | NCT03149770 | PHASE2 | COMPLETED | YES | 2017-09-18 | 2024-04-16 | Details |
| L5668 | NCT04152915 | PHASE1 | COMPLETED | NO | 2019-11-25 | 2021-11-10 | Details |
| L5674 | NCT03228732 | EARLY_PHASE1 | RECRUITING | NO | 2017-12-19 | 2024-11-05 | Details |
| L5686 | NCT02451137 | PHASE4 | COMPLETED | YES | 2015-06-16 | 2019-09-10 | Details |
| L5714 | NCT01010100 | PHASE3 | COMPLETED | NO | 2000-08 | 2010-12-28 | Details |
| L5774 | NCT01472185 | PHASE3 | COMPLETED | YES | 2011-11 | 2014-10-24 | Details |
| L5788 | NCT01201785 | PHASE4 | COMPLETED | YES | 2009-01 | 2012-03-06 | Details |
| L5809 | NCT05153070 | PHASE2 | RECRUITING | NO | 2022-09-21 | 2024-11-21 | Details |
| L5903 | NCT05502562 | COMPLETED | NO | 2023-02-24 | 2024-09-19 | Details | |
| L5933 | NCT05663736 | PHASE4 | UNKNOWN | NO | 2020-01-01 | 2023-03-08 | Details |
| L6000 | NCT01497132 | PHASE4 | COMPLETED | NO | 2012-01 | 2014-09-10 | Details |
| L6086 | NCT00099619 | PHASE3 | COMPLETED | NO | 2004-09 | 2015-02-23 | Details |
| L6111 | NCT02443922 | UNKNOWN | NO | 2015-06 | 2015-05-14 | Details | |
| L6202 | NCT03231709 | PHASE4 | COMPLETED | YES | 2017-08-18 | 2023-12-22 | Details |
| L6239 | NCT00618007 | PHASE2 | COMPLETED | NO | 2008-02 | 2011-06-27 | Details |
| L6264 | NCT05814107 | PHASE1 | UNKNOWN | NO | 2023-05-09 | 2023-06-15 | Details |
| L6307 | NCT01459809 | PHASE3 | COMPLETED | NO | 2012-02 | 2015-01-21 | Details |
| L6309 | NCT01455909 | PHASE3 | WITHDRAWN | NO | 2013-02 | 2012-12-25 | Details |
| L6318 | NCT06269107 | PHASE3 | ACTIVE_NOT_RECRUITING | NO | 2024-02-15 | 2025-01-14 | Details |
| L6337 | NCT04305587 | PHASE1 | COMPLETED | YES | 2020-03-16 | 2024-02-05 | Details |
| L6343 | NCT00562133 | PHASE3 | COMPLETED | NO | 2006-12 | 2007-11-21 | Details |
| L6528 | NCT02585778 | PHASE3 | COMPLETED | YES | 2015-10-23 | 2018-05-17 | Details |
| L6667 | NCT00171561 | PHASE4 | COMPLETED | NO | 2003-03 | 2011-11-08 | Details |
| L6704 | NCT01704378 | PHASE4 | COMPLETED | NO | 2001-04-18 | 2017-02-24 | Details |
| L6726 | NCT00641407 | PHASE4 | COMPLETED | NO | 2007-01 | 2008-03-31 | Details |
| L6782 | NCT03961347 | PHASE2 | ACTIVE_NOT_RECRUITING | NO | 2020-02-01 | 2025-04-02 | Details |
| L6799 | NCT02908087 | PHASE2 | COMPLETED | NO | 2016-03 | 2022-01-11 | Details |
| L6821 | NCT00268645 | PHASE4 | COMPLETED | NO | 2004-09 | 2011-01-11 | Details |
| L6843 | NCT00723411 | PHASE3 | TERMINATED | NO | 2008-07 | 2011-10-10 | Details |
| L6907 | NCT00527397 | PHASE3 | TERMINATED | YES | 2007-08 | 2009-10-15 | Details |
| L6934 | NCT01865305 | PHASE1 | COMPLETED | NO | 2006-09 | 2015-10-23 | Details |
| L7078 | NCT05086445 | PHASE1 | COMPLETED | NO | 2021-11-12 | 2022-11-28 | Details |
| L7100 | NCT02890745 | PHASE2 | COMPLETED | NO | 2016-11 | 2021-06-10 | Details |
| L7148 | NCT03596177 | PHASE2 | COMPLETED | YES | 2018-09-26 | 2023-01-19 | Details |
| L7269 | NCT03367377 | PHASE1 | COMPLETED | NO | 2018-01-03 | 2018-12-11 | Details |
| L7289 | NCT06554054 | PHASE1 | ACTIVE_NOT_RECRUITING | NO | 2024-04-01 | 2024-08-14 | Details |
| L7312 | NCT02825251 | PHASE3 | COMPLETED | YES | 2016-07-06 | 2019-11-21 | Details |
| L7349 | NCT01982253 | PHASE2 | TERMINATED | YES | 2013-10 | 2016-10-07 | Details |
| L7373 | NCT02891954 | PHASE1 | ACTIVE_NOT_RECRUITING | NO | 2016-09 | 2024-11-05 | Details |
| L7386 | NCT00555451 | PHASE1 | COMPLETED | NO | 2007-10 | 2010-05-13 | Details |
| L7392 | NCT02236754 | EARLY_PHASE1 | COMPLETED | YES | 2013-07-02 | 2024-07-23 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00017 | 10973253 | Nat Genet | The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. | Details |
| A00025 | 11443197 | J Clin Endocrinol Metab | Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? | Details |
| A00072 | 15980866 | Nat Med | Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis. | Details |